» Articles » PMID: 9494007

Rectal Cancer Following Colectomy and Ileorectal Anastomosis for Familial Adenomatous Polyposis

Overview
Journal Aust N Z J Surg
Specialty General Surgery
Date 1998 Mar 11
PMID 9494007
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Familial adenomatous polyposis (FAP) has historically been treated by colectomy and ileorectal anastomosis (IRA). Preservation of the rectum allows the subsequent development of cancer in the rectum. The risk of rectal cancer following ileorectal anastomosis in the Australian population has not been published to date.

Methods: An audit of the Familial Adenomatous Polyposis Registry of Western Australia was undertaken to assess patients who had undergone colectomy and ileorectal anastomosis. Fifty-five patients ranging in age from 13 to 65 years were studied.

Results: Seven patients (13%) developed cancer of the rectum with a median follow-up of 10 years (range: 1-31 years). Median interval to diagnosis of carcinoma of the rectum following colectomy and IRA was 10 years. All patients who developed cancer in the retained rectum had rectal polyps. Colon cancer was present in the initial colectomy specimen in 13 patients (of these, five patients developed rectal cancer). Flat polyps were noted in five patients. Four patients with flat polyps developed cancer of the rectum.

Conclusions: Total colectomy and IRA should be considered as part 1 of a staged procedure in the patient with FAP. With the exception of the patient with no evidence of rectal polyps, completion proctectomy should be undertaken within 10 years of the initial colectomy.

Citing Articles

Endoscopic management of patients with familial adenomatous polyposis after prophylactic colectomy or restorative proctocolectomy - systematic review of the literature.

Gavric A, Sanchez L, Brunori A, Bravo R, Balaguer F, Pellise M Radiol Oncol. 2024; 58(2):153-169.

PMID: 38860690 PMC: 11202397. DOI: 10.2478/raon-2024-0029.


Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.

Burke C, Dekker E, Samadder N, Stoffel E, Cohen A BMC Gastroenterol. 2016; 16(1):87.

PMID: 27480131 PMC: 4969736. DOI: 10.1186/s12876-016-0494-4.


Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human.

Alberici P, de Pater E, Cardoso J, Bevelander M, Molenaar L, Jonkers J Am J Pathol. 2007; 170(1):377-87.

PMID: 17200209 PMC: 1762685. DOI: 10.2353/ajpath.2007.060853.